Recombinant Mouse CD22 protein (His Tag)
Species
Mouse
Purity
>90 %, SDS-PAGE
Tag
His Tag
Activity
not tested
Cat no : Eg1324
Validation Data Gallery
Product Information
| Purity | >90 %, SDS-PAGE |
| Endotoxin | <0.1 EU/μg protein, LAL method |
| Activity |
Not tested |
| Expression | HEK293-derived Mouse CD22 protein Ser22-Arg708 (Accession# P35329-1) with a His tag at the C-terminus. |
| GeneID | 12483 |
| Accession | P35329-1 |
| PredictedSize | 77.8 kDa |
| SDS-PAGE | 90-120 kDa, reducing (R) conditions |
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| Storage Conditions |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
CD22, also known as Siglec-2 (sialic acid binding Ig-like lectin 2) or BL-CAM (B-lymphocyte cell adhesion molecule), is a 130-140 kDa, B-cell restricted, type I transmembrane glycoprotein belonging to the immunoglobulin gene superfamily. The expression of CD22 is developmentally regulated. It is expressed at low levels in the cytoplasm of pro-B and pre-B cells and present on the cell surface only at mature stages of B-cell differentiation. Cell surface expression is lost during terminal differentiation into plasma cell and after B-cell activation. CD22 is an inhibitory receptor for B-cell receptor (BCR) signalling, preferentially binds to alpha-2,6-linked sialic acid and mediates B-cell B-cell interactions. It plays a crucial role in activation and differentiation of the B-cell.
References:
1. Engel, P et al. The Journal of experimental medicine vol. 181,4 (1995): 1581-6. 2. Poe, Jonathan C, and Thomas F Tedder. Trends in immunology vol. 33,8 (2012): 413-20. 3. Chen, Jie et al. Oncotarget vol. 7,35 (2016): 56129-56146.